Roche Aktie

354,80 EUR -5,80 EUR -1,61 %

13:31:30

STU

354,60 EUR -7,20 EUR -1,99 %

13:35:35

HAML

Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.286,34 Mrd. EUR

KGV20,72Div. Rendite3,22%

WKN851311

ISINCH0012032113

SymbolRHHBF

Roche Aktien News

Sortieren:Datum Meistgelesen

31.03.26ZacksThe Zacks Analyst Blog Roche Holding, AT&T and Amgen

30.03.26ZacksTop Stock Reports for Roche, AT&T & Amgen

30.03.26Roche Holding AGRoche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

WerbungRoche-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

23.03.26Roche Holding AGRoche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development

17.03.26BenzingaNVIDIA Meets Healthcare - Roche To Build Massive AI Factory With NVIDIA To Speed Up Diagnostics, Therapies

16.03.26Roche Holding AGRoche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

10.03.26Roche Holding AGRoche Annual General Meeting 2026

09.03.26Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

06.03.26ZacksRoche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal

06.03.26Roche Holding AGNew England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

05.03.26Roche Holding AGRoche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

25.02.26ZacksThe Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT

25.02.26ZacksTop Stock Reports for Costco, Roche & Lam Research

20.02.26Roche Holding AGFDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer

17.02.26Roche Holding AGChange to the Roche Enlarged Corporate Executive Committee

16.02.26Roche Holding AGRoche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

09.02.26BenzingaRoche Says Experimental Drug Helped Slow Disability In Progressive Multiple Sclerosis Study

07.02.26Roche Holding AGRoche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

29.01.26BenzingaRoche Sees Steady 2026 Growth As Key Drugs Post Double-Digit Gains

29.01.26Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth

28.01.26ZacksRoche Reports Upbeat Efficacy Data From Phase II Obesity Study

27.01.26Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

08.01.26ZacksThe Zacks Analyst Blog Highlights Micron Technology, Roche and UnitedHealth

08.01.26RTE.ieSeverance costs hit profits at Irish arm of Roche

07.01.26ZacksTop Stock Reports for Micron Technology, Roche & UnitedHealth

22.12.25BenzingaUS Medicaid Program Will Hit Swiss Wallets Hard, Roche CEO Says

22.12.25Roche Holding AGFDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma

18.12.25BenzingaWhite House Readies Drug Price Deals With AbbVie, Novartis, Roche

16.12.25PR NewswireRoche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities

11.12.25Roche Holding AGRoche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu

10.12.25Roche Holding AGRoche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

09.12.25Roche Holding AGRoche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark

09.12.25Roche Holding AGEuropean Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis

08.12.25Roche Holding AGRoche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

08.12.25Roche Holding AGRoche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study

02.12.25Roche Holding AGRoche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)

25.11.25ZacksThe Zacks Analyst Blog Highlights Alphabet, Roche, RTX, Crawford United and C&F Financial

24.11.25ZacksTop Stock Reports for Alphabet, Roche & RTX

19.11.25Roche Holding AGEuropean Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma

18.11.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.